A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]) to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2016
At a glance
- Drugs CERE 120 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Ceregene
- 01 Apr 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2007 New trial record.